Back to News
Market Impact: 0.25
Ginkgo Datapoints Partners With Lilly TuneLab To Link AI Models And Lab Data
Source: Nasdaq
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
Ginkgo Bioworks announced a new agreement for its Ginkgo Datapoints offering with Lilly TuneLab, Eli Lilly's AI/ML drug-discovery platform. The partnership expands Ginkgo's presence in AI-enabled biotechnology and drug discovery, though no financial terms or expected revenue contribution were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
DNA0.50
LLY0.20
More News
- Stocks started the week with promise but ended in despair. Our take on the big reversal
- Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030
- 2 Stocks Billionaires Can't Stop Buying
- Companies promised AI gains— here's how the payoff showed up in earnings
- AWS grows 39% and Amazon will spend even more on AI in 2027
- U.S workers just took home their smallest share of capital since at least 1947—and the lowest ever recorded